Sun Pharmaceutical Industries

Sun Pharma Boosts Dermatology Offering with Concert Buy

Indian drugmaker Sun Pharmaceutical Industries is to buy US biotech Concert Pharmaceuticals, gaining access to the latter’s lead product candidate deuruxolitinib for treating an autoimmune dermatological disease.

India’s Sun Pharmaceutical to Buy Compatriot Ranbaxy

Swedish Drugmaker Meda Spurns Mylan Approach

Teva, Sun Pharma to Pay $2.15 Billion to Settle Pfizer Patent Suit

India's Sun Pharma Wins over Taro with Higher Offer

U.S. Court Upholds Pfizer's Lyrica Patent Protection

US Top Court Rules for Generic Drugmaker on Patent

Sun Pharma To Sell Some Merck Diabetes Drugs In India